Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...

Gilead Sciences Inc. closed 9.97% short of its 52-week high of $119.96, which the company reached on March 10th.

Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising ...

The budget cuts threaten global progress on everything from heart disease to H.I.V. — and could affect American drug ...

Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. | Following a ...

Delve into the STAT6 degrader technology and what it could bring to inflammatory and allergic disease treatment.

The National Weather Service issued a report at 9:14 p.m. EDT on Tuesday for strong thunderstorms until 10 p.m. EDT for St.

This month, lenacapavir is expected to receive FDA approval for pre-exposure prophylaxis (PrEP). It could very well be that ...

Aisera enables businesses to deliver transformative work experiences, boost employee productivity, and reduce operational costs with its award-winning AI agent platform. Aisera has been recognized as ...

The chronic hepatitis B market size is predicted to surge owing to the increasing prevalence of the disease globally and ...

The “March of Dissent” rally on Saturday was in response to the lack of abortion access in Texas among other concerns, an ...

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal ...